SCHEMBL330030

SCHEMBL330030

[CH2]Cc1ccc(C(C)C)cc1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.52
PYCR1 P32322 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
TYR P14679 2/20 0.41
RAB9A P51151 3/20 0.40
NPC1 O15118 2/20 0.40
HTR1D P28221 1/20 0.40
HTR1B P28222 1/20 0.40
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
RXRA P19793 1/20 0.38
RXRB P28702 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
BCHE P06276 1/20 0.38
ACHE P22303 1/20 0.38
NLRP3 Q96P20 1/20 0.38
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1610104 0.80 IDO1 (0.48) IDO1PYCR1L3MBTL1TYRRAB9A
SCHEMBL27674021 0.80 NOS3 (0.41) IDO1
SCHEMBL9642338 0.79 IDO1 (0.52) IDO1PYCR1L3MBTL1TYRRAB9A
SCHEMBL1611733 0.78 NPC1 (0.45) RAB9ANPC1SMN1; SMN2HPGD
SCHEMBL10729588 0.78 IDO1 (0.56) IDO1PYCR1L3MBTL1TYRRAB9A
SCHEMBL3956146 0.78 IDO1 (0.56) IDO1PYCR1L3MBTL1TYRRAB9A
SCHEMBL11341386 0.77 IDO1 (0.68) IDO1PYCR1L3MBTL1TYRRAB9A
SCHEMBL1610592 0.77 IDO1 (0.45) IDO1PYCR1L3MBTL1RAB9ANPC1
SCHEMBL104124 0.76 TYR (0.58) IDO1TYRRAB9ANPC1HTT
SCHEMBL1803971 0.76 ESR1 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240117092-A1 OPTICALLY ACTIVE DEVICES AMO Ireland (IE) 2024-04-11 US claimed
EP-4263513-A1 OPTICALLY ACTIVE DEVICES AMO Ireland (IE) 2023-10-25 EP claimed
WO-2022128832-A1 OPTICALLY ACTIVE DEVICES MERCK PATENT GMBH (DE) 2022-06-23 WO claimed
EP-2407511-B1 Thermoplastic resin composition CHEIL IND INC (KR) 2017-03-22 EP claimed
CN-102250458-B Poly carbonate resin composition and moulded product thereof CHEIL INDUSTRIES INC. (KR) 2016-01-27 CN claimed
US-8557912-B2 Thermoplastic resin composition CHEIL INDUSTRIES INC. (KR) 2013-10-15 US claimed
EP-2582409-A1 HIGH REFRACTIVE INDEX, ACRYLIC OPHTHALMIC DEVICE MATERIALS WITH REDUCED GLISTENINGS Novartis AG (CH) 2013-04-24 EP claimed
US-20120016068-A1 Thermoplastic Resin Composition CHEIL INDUSTRIES INC. (KR) 2012-01-19 US claimed
EP-2407511-A1 Thermoplastic resin composition Cheil Industries Inc. (KR) 2012-01-18 EP claimed
WO-2011163126-A1 HIGH REFRACTIVE INDEX, ACRYLIC OPHTHALMIC DEVICE MATERIALS WITH REDUCED GLISTENINGS NOVARTIS AG (CH) 2011-12-29 WO claimed
US-6774212-B2 FOR THERAPY OF VIRAL INFECTION OR AS AN ASSAY STANDARD OR REAGENT BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-08-10 US claimed
US-6699855-B2 PYRROLOPYRAZINONES USEFUL AS SERINE PROTEASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2004-03-02 US claimed
EP-1177227-B1 WATER PLASTICIZED HIGH REFRACTIVE INDEX POLYMER FOR OPHTHALMIC APPLICATIONS SURGIDEV CORP (US) 2003-10-01 EP claimed
US-20020128417-A1 Water plasticized high refractive index polymer for ophthalmic applications SURGIDEV CORPORATION (US) 2002-09-12 US claimed
US-20020065248-A1 Inhibitors of hepatitis C virus NS3 protease BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-05-30 US claimed
EP-1177227-A1 WATER PLASTICIZED HIGH REFRACTIVE INDEX POLYMER FOR OPHTHALMIC APPLICATIONS SURGIDEV CORPORATION (US) 2002-02-06 EP claimed
US-20020007032-A1 Water plasticized high refractive index polymer for ophthalmic applications SURGIDEV CORPORATION (US) 2002-01-17 US claimed
US-20010056165-A1 Water plasticized high refractive index polymer for ophthalmic applications SURGIDEV CORPORATION (US) 2001-12-27 US claimed
US-6281319-B1 HYDRATABLE POLYMER SURGIDEV CORPORATION 2001-08-28 US claimed
WO-2000061646-A1 WATER PLASTICIZED HIGH REFRACTIVE INDEX POLYMER FOR OPHTHALMIC APPLICATIONS SURGIDEV CORPORATION (US) 2000-10-19 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020065248-A1 Inhibitors of hepatitis C virus NS3 protease TMPRSS15, CTRC, CPN1 IDO1 1672/4885PYCR1 1252/4885L3MBTL1 2982/4885
US-20240117092-A1 OPTICALLY ACTIVE DEVICES PDE6C, UACA, PDE6A IDO1 3006/4885PYCR1 642/4885L3MBTL1 4771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.